soul trial oral semaglutide cardiovascular outcomes results 2025 nejm align more closely with attained dose than achieved weight loss NEJM Editorial Fellow Harleen Marwah,

Glucagon-like peptide-1 receptor agonists and dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists in the treatment of obesity/metabolic syndrome, prediabetes/diabetes and non-alcoholic fatty liver diseaseCurrent evidence

Lancet 362(9380):263270 Channappanavar R, Perlman S (2017) Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology

In such cases, the guideline instructs you to assign the appropriate code for the drug use, abuse, or dependence instead. So, per this guideline, we can assume that you should report long-term drug use other than in cases of addiction, or for conditions such as detoxification or drug withdrawal, with a Z79 code

Closing Thoughts The trial gives a non-prescription weight-management option a controlled, six-month evidence base

Known interactions Naloxone: Research suggests naloxone may block DSIP's effects